Design Therapeutics, Inc.
Design Therapeutics, Inc. is listed today as Design Therapeutics, Inc.: market value, financials and filings are on its company page.
Funding rounds
2 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jan 2021 | $125 M | No. 2 | $50 to $250 million | equity | SEC | |
| Feb 2020 | $46 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Design Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Feb 2021).
SEC Form D · Feb 2021
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Feb 2021
That is all the official record says: Design Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Design Therapeutics, Inc. are on record.
Investors#
8 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Cormorant Asset Management, LP | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Cormorant Global Healthcare Master Fund, LP | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Cormorant Private Healthcare Fund III LP | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Cormorant Private Healthcare Fund II, LP | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Quan Venture Fund II, L.P. | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| SR One Capital Fund I Aggregator LP | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| SR One Capital Management, LLC | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| SR One Capital Partners I, LP | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 26 investors.
Largest shareholders today
Institutions holding Design Therapeutics, Inc. shares, as of Sep 30, 2026.
- DUNHAM TRUST Co$96 M11.98%
- SR One Capital Management, LP$82 M10.19%
- Driehaus Capital Management LLC$46 M5.70%
- Baker Bros. Advisors LP$38 M4.67%
- BlackRock, Inc.$34 M4.24%
- Trails Edge Capital Partners, LP$31 M3.90%
- Point72 Asset Management, L.P.$29 M3.62%
- Frazier Life Sciences Management, L.P.$23 M2.83%
- State Street Corp$21 M2.61%
- Vanguard Capital Management LLC$21 M2.61%
- Vivo Capital, LLC$20 M2.52%
- Caption Management, LLC$17 M2.09%
- Deep Track Capital, LP$17 M2.07%
- Sofinnova Investments, Inc.$14 M1.79%
- Kennedy Capital Management LLC$13 M1.60%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Joao Siffert, M.D. | Executive officer | Feb 2021 |
| Pratik Shah, Ph.D. | Executive officer | Feb 2021 |
| Sean Jeffries, Ph.D. | Executive officer | Feb 2021 |
| Sean Z. Jeffries, Ph.D. | Executive officer | Jun 2020 |
| Arsani William, M.D. | Director | Feb 2021 |
| Joao Siffert, M.D. | Director | Feb 2021 |
| John Schmid | Director | Feb 2021 |
| Pratik Shah, Ph.D. | Director | Feb 2021 |
| Rodney Lappe, Ph.D. | Director | Feb 2021 |
| Simeon George, M.D. | Director | Feb 2021 |
| Stella Xu, Ph.D. | Director | Feb 2021 |
| Aseem Z. Ansari, Ph.D. | Director | Jun 2020 |
| Rodney Z. Lappe, Ph.D. | Director | Jun 2020 |
| Simeon Z. George, M.D. | Director | Jun 2020 |
| Stella Z. Xu, Ph.D. | Director | Jun 2020 |
Went public since 2021. Its SEC number is that of a company listed on a stock exchange.